Sat, Jan 31, 2015, 9:00 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • tazamatic2002 tazamatic2002 Dec 19, 2013 3:25 PM Flag

    I would post links but Yahoo blocks that now

    I am a Geron long and I will Quote John Scarlett on the MF space. There is room in the space for Imetelstat and Jakifi. He projects that Gerons share of the Market would provide a Revenue stream of about $400 million to $600 million a year, He also said I had MF and I could take a drug that had a 20% chance of putting me in complete remission I would jump on it.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Man you are really getting desperate!!!!

    • OK, that's good! Talk to Scarlett about the JAK STAT pathway, different jak inhibitors, their different mechanisms of action, chemical structure etc! Once the FDA sanctions a registrational or pivotal trial for GERN's drug please come and let us know! I would seriously consider buying GERN once the FDA has approved a registrational trial! I really dont invest ever based on a Phase 1 single center single arm trial with a small sample size where the investigator and not the drug company called the shots and wily nilly changed protocols during the trial! As you know the FDA would NEVER allow that for any registrational trial and certainly would not accept a single center, small sample size, single arm non-placebo controlled trial, where the side effects of the non-responders are never fully detailed by the study investigator!

 
INCY
79.71-1.63(-2.00%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.